Clinical trial

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

NCT03732664

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2018-10-01

PhasePHASE1

Study timeline

Study start (actual)2018-10-01Date precision: day

Registry last updated2023-03-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

High-Risk Resectable NSCLCunresolved

Interventions

Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, Sintilimab, Tislelizumab, DurvalumabDRUG

Sponsors & collaborators

Second Affiliated Hospital, Zhejiang University, School of Medicinelead sponsor

Mapped research locations

HangzhouZhejiang, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03732664 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.